Novo Nordisk A/S: Monlunabant phase 2a trial in obesity …
WEB9 hours ago · NVO. Novo Nordisk A/S. Bagsværd, Denmark, 20 September 2024 – Novo Nordisk today announced headline results from a phase 2a clinical trial with monlunabant, a small molecule oral cannabinoid...
Novo Nordisk A/S: Monlunabant phase 2a trial in obesity
WEB9 hours ago · Bagsværd, Denmark, 20 September 2024 – Novo Nordisk today announced headline results from a phase 2a clinical trial with monlunabant, a small molecule oral cannabinoid receptor 1 (CB1) inverse ...
Novo Nordisk's Monlunabant Data Drags Stocks Of Smaller Players
WEB2 hours ago · Earlier on Friday, Novo Nordisk A/S (NYSE: NVO) announced headline results from a phase 2a clinical trial with monlunabant, a small-molecule oral cannabinoid receptor 1 (CB1) inverse agonist.
Novo Nordisk A/S: Monlunabant phase 2a trial in obesity …
WEB9 hours ago · The trial investigated the efficacy and safety of a once-daily 10 mg, 20 mg and 50 mg dose of monlunabant compared to placebo on body weight after 16 weeks in 243 people with obesity and metabolic syndrome 1. People were equally randomised among the four treatment arms.
Novo Nordisk’s obesity newcomer monlunabant heads into …
WEB6 hours ago · Novo Nordisk has announced positive Phase IIa results for monlunabant, a small molecule oral CB1 inverse agonist for obesity. The trial showed significant weight loss with a 10 mg dose, achieving a 7.1 kg reduction versus 0.7 kg for placebo.
Novo Nordisk Slips On Phase 2a Clinical Trial Result With Monlunabant
WEB6 hours ago · Friday, shares of Novo Nordisk A/S are sliding following the announcement of safety results of phase 2a clinical trial of Monlunabant compared to placebo in patients with obesity and metabolic syndrome. Monlunabant, formerly INV-202, is a small molecule oral cannabinoid receptor 1 or CB1 inverse agonist.
Novo Nordisk Stock Declines After Headline Results From Mid …
WEB5 hours ago · Friday, Novo Nordisk A/S (NYSE:NVO) announced headline results from a phase 2a clinical trial with monlunabant, a small-molecule oral cannabinoid receptor 1 (CB1) inverse agonist.
Novo Nordisk shares drop nearly 5% on disappointing obesity pill …
WEB7 hours ago · Novo Nordisk's shares fell nearly 5% on Friday after results from a Phase 2a trial of the Danish drugmaker's experimental obesity pill monlunabant came in below market expectations.
Novo Shares Fall After Mixed Safety Data on New Weight-Loss Drug
WEB7 hours ago · Monlunabant generates statistically significant weight loss; Mild to moderate anxiety, irritability, sleep issues reported
Novo’s obesity drug linked to ‘neuropsychiatric side effects’
WEB7 hours ago · The Danish Big Pharma gained its CB1 receptor blocker, now known as monlunabant, as part of the acquisition of Canada’s Inversago in a vague deal that Novo described at the time as being worth...
- Some results have been removed